Find and Pitch Jounalists, Get Your Story Covered

Tags: cabozantinib atezolizumab prostate cancer docetaxel castrate-resistant prostate cancer

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 5 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 9 days ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - about 1 month ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - 8 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - 8 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 9 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - 9 months ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - 10 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 10 months ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - 10 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - 11 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness - 6 days ago
3	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 8 days ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - about 1 month ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - about 1 month ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 7 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 7 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 7 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 7 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 9 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 10 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - 10 months ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - 10 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - 11 months ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - 12 months ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - 12 months ago
4	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 28 days ago
5	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - about 1 month ago
6	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - about 1 month ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 6 months ago Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC - 6 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - 10 months ago
7	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 3 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 3 months ago Regorafenib-Pembrolizumab Has 'Modest' Activity in HCC Post-Immunotherapy - 3 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - 7 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 9 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 9 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 9 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 10 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 10 months ago
8	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 3 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 7 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - 9 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - 11 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - 11 months ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 7 months ago Phase 3 Results Show First-Line Amivantamab-vmjw Plus Chemotherapy Prolongs Survival In Patients With Advanced or Metastatic NSCLC - 8 months ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - 8 months ago Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - 8 months ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - 10 months ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - 10 months ago

Journalists covering cabozantinib